Gene Logic to Revive Drugs for Organon, Will Own Half of Any Resulting Txs; Posts Disappointing Q1 | GenomeWeb

Gene Logic plans to help Organon Pharmaceuticals find new uses for a number of failed compounds, the company said last week. In a twist on Gene Logic's standard repositioning deal, the company will own half of any compound that Organon decides to pursue.

Separately, Gene Logic reported a decline in first-quarter revenue and widened net losses, but said the Organon deal signals that its drug-repositioning business is starting to gain steam.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.